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ABSTRACT
Objective To examine all cause and disease specific
mortality in patients with osteoarthritis of the knee or hip.
Design Population based cohort study.
Setting General practices in the southwest of England.
Participants 1163 patients aged 35 years or over with
symptoms and radiological confirmation of osteoarthritis
of the knee or hip.
Main outcome measures Age and sex standardised
mortality ratios and multivariable hazard ratios of death
after a median of 14 years’ follow-up.
Results Patients with osteoarthritis had excess all cause
mortality compared with the general population
(standardised mortality ratio 1.55, 95% confidence
interval 1.41 to 1.70). Excess mortality was observed for
all disease specific causes of death but was particularly
pronounced for cardiovascular (standardised mortality
ratio 1.71, 1.49 to 1.98) and dementia associated
mortality (1.99, 1.22 to 3.25). Mortality increased with
increasing age (P for trend <0.001), male sex (adjusted
hazard ratio 1.59, 1.30 to 1.96), self reported history of
diabetes (1.95, 1.31 to 2.90), cancer (2.28, 1.50 to 3.47),
cardiovascular disease (1.38, 1.12 to 1.71), and walking
disability (1.48, 1.17 to 1.86). However, little evidence
existed for increased mortality associated with previous
joint replacement, obesity, depression, chronic
inflammatory disease, eye disease, or presence of pain at
baseline. The more severe the walking disability, the
higher was the risk of death (P for trend <0.001).
Conclusion Patients with osteoarthritis are at higher risk
of death comparedwith the general population. History of
diabetes, cancer, or cardiovascular disease and the
presence of walking disability are major risk factors.
Management of patients with osteoarthritis and walking
disability should focus on effective treatment of
cardiovascular risk factors and comorbidities, as well as
on increasing physical activity.
INTRODUCTION
The morbidity associated with chronic rheumatic dis-
eases is well documented, and arthritis is the leading
cause of chronic pain and physical disability in the
community.1 Mortality associated with arthritis is less
well characterised.2However, inflammatorydisorders,
such as rheumatoid arthritis, may result in excess
mortality.3 Estimates of the standardised mortality
ratio in rheumatoid arthritis vary from about 1.3 to
3.0.4 The main reason for this excess mortality is
cardiovascular disease, although deaths from infec-
tions, respiratory diseases, and gastrointestinal disor-
ders are also increased.4 The excess in cardiovascular
mortality in rheumatoid arthritis is thought to be inpart
a result of vascular disease being a component of the
general inflammatory process and in part a result of
drug treatments such as steroids and non-steroidal
anti-inflammatory drugs.5 Immobility resulting from
arthritis may also shorten lifespan; for example, a
recent study showed that disability in older people
was an important risk factor for increased mortality
independent of age and comorbid conditions.6
Very little is known aboutmortality in osteoarthritis,
although it is by far the most common form of rheu-
matic disease.7 Osteoarthritis is not an inflammatory
condition and is treated with anti-inflammatory drugs
rather than with steroids.8 The condition often results
in immobility,9 and obesity is a major comorbidity in
patients with osteoarthritis.10 Thus, reasons exist for
thinking that people with osteoarthritis may have an
excess in mortality as well as in morbidity. Hochberg
recently reviewed the literature on mortality in
osteoarthritis.2 He found seven studies, several of
which suggested an increased risk of death in people
with osteoarthritis,11-18 but these studies had several
methodological problems.2
Osteoarthritis is a common cause of medical
consultation.19 A better understanding of the burden
of osteoarthritis in terms not only of symptoms but
also of a reduced life expectancy, and an investigation
into potentially modifiable risk factors, could inform
future management strategies beyond the current
focus on treating the symptoms.8 Therefore, we used
data from a large population based study to determine
whether people with osteoarthritis of the knee or hip
are subject to an increased risk of death and to examine
the causes and potential risk factors.20 21
METHODS
Patients
The Somerset and Avon Survey of Health is a popula-
tion based study of 28080 people aged 35 years or over
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randomly selected from40general practices in the south
west of England.2021 The survey excluded 2034 people
who hadmoved out of the study area, had a severemen-
tal or terminal illness, or had died. The remaining 26046
people were sent a screening questionnaire comprising
questions on general health, use of health services, and
symptoms of hip and knee disease. Non-respondents
were sent two reminders and contacted by phone, if
necessary.2223 People were screened for knee and hip
pain with a modified version of the question used in
the first National Health and Nutrition Examination
Survey.10 The invitation for clinical examination and
examination of patients with knee or hip pain was orga-
nised in two phases according to the geographical loca-
tion of the participating practices in 1994-5.
Procedures
We used data collected at baseline on demographic
and socioeconomic characteristics, self reported health
conditions and drug use, and presence of knee or hip
pain and walking disability as potential predictors of
mortality. Participants reported presence or absence
of several comorbidities, which were grouped as fol-
lows: cardiovascular disease (angina, myocardial
infarction, heart failure, claudication, and stroke), can-
cer, chronic obstructive pulmonary disease (including
asthma, bronchitis, and emphysema), arterial hyper-
tension, diabetes, chronic inflammatory disease
(including rheumatoid arthritis), eye disease (cataract
or glaucoma), anddepression.We classified bodymass
index (kg/m2) into two categories: non-obese (<30)
and obese (≥30). We classified the self reported use of
oral analgesics into use of paracetamol, non-steroidal
anti-inflammatory drugs, and opioids, irrespective of
the dosage.
In 1994-5, examined participants were asked about
knee or hip pain with the following questions: “In the
past 12 months, have you had pain in or around your
left (right) knee (hip) on most days for one month or
longer during the day (night)? (yes/no).” We consid-
eredparticipants to have pain if they reportedpain dur-
ing the day or night in at least one hip or knee.24
Participants were asked about their walking disability:
“How difficult is it for you to go outdoors and walk
down the road on your own? (not difficult/quite diffi-
cult/very difficult/impossible).”24 We considered
patients to have disability if walking was described at
least to be “quite difficult.” Survival status of the 2703
participants and information on the cause of death up
to 9 February 2009 came from the Office for National
Statistics, London. The causes of death were registered
and coded according to ICD-9 (international classifica-
tion of diseases, 9th revision) or ICD-10. We recoded
all to ICD-10 and considered death to be caused by the
primary cause of death listed on the death certificate
with ICD-10 codes of “I” for cardiovascular disease,
“C” for cancer, “J” for respiratory disease, “K” for
gastrointestinal disease, and “F01,” “F03,” or “R54”
for dementia associated disease.
At baseline, participants had weight bearing antero-
posterior and lateral radiographs of the knees and hip
according to a standardised protocol. Details of the
radiographic examinations are described elsewhere.24
We assigned Kellgren-Lawrence grades of global
radiological severity on anteroposterior views by
using a scale from 0 to 4 (0=no features of osteoarthri-
tis; 1=minute osteophytes of doubtful significance;
2=definite osteophytes, no definite joint space narrow-
ing; 3=definite joint space narrowing of a moderate
degree; 4=severe joint space impairment).25 We
considered osteoarthritis to be present if a Kellgren-
Lawrence grade of at least 1 was measured for at least
one joint.
Statistical analysis
We compared mortality between included patients
with osteoarthritis of the knee or hip and the general
population in England and Wales by calculating stan-
dardised mortality ratios (the ratio of observed to
expected number of deaths) and corresponding 95%
Original random sample (n=28 080)
Patients alive (n=725)Patients died (n=438)
Included in analysis (n=725)Included in analysis (n=438)
Excluded (n=163):
  Films requested, not received (n=154)
  Knee or hip implant (n=9)
Excluded (n=2034)
Screening questionnaire sent (n=26 046)
Non-responders (n=3068)
Responded to screening questionnaire (n=22 978)
Considered for clinical examination (n=6435)
Clinically examined (n=2703)
Had radiographic examination of knee or hip (n=1766)
No knee or hip pain (n=16 543)
Had radiographs of knee or hip read (n=1603)
 No knee or hip osteoarthritis (n=440)
Patients with osteoarthritis (n=1163)
Survival status ascertained (n=1163)
 Lost to follow-up (n=0)
Excluded (n=3732):
  Not invited (n=2079)
  Invited, but refused (n=1653)
No radiographic examination (n=937):
  Refused (n=449)
  Unable to attend (n=223)
  Logistical reasons (n=120)
  Reason unclear (n=145)
Fig 1 | Flow of participants through different stages of study
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confidence intervals. Expected numbers of deaths
came fromage and sex specificmortality data provided
in the mortality statistics from 2002 (Office for
National Statistics, London) in 10 year age bands,
andwe used the age at themid-point of the observation
time to assign study patients to age bands. In univari-
able andmultivariableCoxproportional hazardsmod-
els, we examined associations between all cause and
disease specificmortality and characteristics of patients
at baseline, and we tested associations with two sided
Wald tests. We accounted for missing data in the
baseline covariates by using multiple imputation with
overall mortality, log transformed survival time, sex,
age, social class, smoking, comorbid conditions, use
of analgesics, previous joint replacement, type of
osteoarthritis, knee or hip pain and walking disability,
and study characteristics such as recruitment cycle as
variables in the imputation model, to create 20
imputed datasets.26-28
In sensitivity analyses, we examined associations
between overall mortality and baseline characteristics
by using multivariable Cox proportional hazards
regression models restricted to patients with radio-
graphic osteoarthritis defined by a more stringent
Kellgren-Lawrence grade of at least 2 and restricted
to patients with complete information on covariates.
Nelson-Aalen estimates of cumulative hazards and sta-
tistical tests based on Schoenfeld residuals indicated
that proportional hazards assumptions were satisfied,
and Cox-Snell residuals indicated a satisfactory model
fit. Finally, we compared numbers and percentages of
characteristics at baseline between participants who
were invited but did not attend, those who attended
clinical examination only, and those with clinical and
radiographic examination. All P values and 95% con-
fidence intervals are two sided.
RESULTS
Figure 1 shows the flow of participants through the
study. Of 22 978 responders to the screening question-
naire, 6435 participants were considered, 4356 were
invited for a clinical examination, and 2703 attended;
1766 (65%) had a radiographic examination of their
knees or hips, and we included 1163 (43%) patients
with radiologically confirmed osteoarthritis of the
knee or hip in the analyses. Web appendix 1 shows a
comparison of participants who were invited but did
not attend, those who attended for a clinical examina-
tion only, and those with clinical and radiographic
examination. Participants who had radiographic
examination were younger than the remainder of par-
ticipants. No relevant differences existed for the other
characteristics at baseline.
At the end of follow-up, 725 (62%) of the included
patients were still alive; 188 (16%) died from cardio-
vascular disease, 123 (11%) died from cancer, 43
(3.7%) died from respiratory disease, 19 (1.6%) died
from gastrointestinal disease, 16 (1.4%) died from
Table 1 | Age and sex standardised mortality ratios
Cause of death
All patients (n=1163) Men (n=503) Women (n=660)
No of deaths
SMR (95% CI)
No of deaths
SMR (95% CI)
No of deaths
SMR (95% CI)Observed Expected Observed Expected Observed Expected
All causes 438 283 1.55 (1.41 to 1.70) 204 129 1.58 (1.38 to 1.81) 234 154 1.52 (1.34 to 1.73)
Cardiovascular disease 188 110 1.71 (1.49 to 1.98) 95 52 1.82 (1.49 to 2.22) 93 57 1.62 (1.32 to 1.98)
Cancer related 123 93 1.32 (1.10 to 1.57) 58 44 1.33 (1.03 to 1.72) 65 50 1.31 (1.03 to 1.67)
Respiratory disease 43 33 1.29 (0.96 to 1.74) 20 15 1.38 (0.89 to 2.14) 23 19 1.22 (0.81 to 1.84)
Gastrointestinal disease 19 13 1.47 (0.94 to 2.30) 6 6 1.09 (0.49 to 2.42) 13 7 1.75 (1.02 to 3.01)
Dementia associated 16 8 1.99 (1.22 to 3.25) 5 2 2.29 (0.95 to 5.50) 11 6 1.88 (1.04 to 3.39)
SMR=standardised mortality ratio.
Age (years) at baseline*:
  55-74
  ≥75
Male sex
Lower social class
Smoking at baseline
Previous joint replacement
Type of osteoarthritis†:
  Hip only
  Knee and hip
Knee or hip pain
Walking disability
Analgesics:
  Paracetamol
  NSAIDs
  Opioids
Arterial hypertension
Cancer
Cardiovascular disease
Chronic inflammatory disease
Chronic obstructive pulmonary disease
Depression
Diabetes
Eye disease
Obesity
12.0 (5.34 to 27.2)
41.0 (17.9 to 94.0)
1.59 (1.30 to 1.96)
1.12 (0.92 to 1.37)
1.22 (0.95 to 1.57)
1.12 (0.81 to 1.57)
1.14 (0.88 to 1.47)
1.10 (0.88 to 1.39)
0.89 (0.72 to 1.09)
1.48 (1.17 to 1.86)
1.20 (0.93 to 1.55)
0.92 (0.73 to 1.15)
0.98 (0.75 to 1.29)
1.16 (0.93 to 1.43)
2.28 (1.50 to 3.47)
1.38 (1.12 to 1.71)
1.01 (0.82 to 1.24)
1.17 (0.91 to 1.51)
0.96 (0.68 to 1.36)
1.95 (1.31 to 2.90)
1.09 (0.82 to 1.44)
0.83 (0.65 to 1.04)
<0.001
<0.001
0.25
0.12
0.49
0.58
0.25
0.001
0.17
0.47
0.90
0.18
<0.001
0.003
0.93
0.22
0.83
0.001
0.56
0.11
0.25 0.5 1.0 2.0 4.0
Characteristic
Higher mortality
in reference
category
Lower mortality
in reference
category
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
P value
Fig 2 | Associations between characteristics at baseline and all cause mortality up to 15 years
thereafter. Shows hazard ratios with corresponding 95% confidence intervals from
multivariable Cox proportional hazards models after multiple imputation of missing values in
covariates. P values were calculated by using two sided Wald tests. NSAIDs=non-steroidal anti-
inflammatory drugs. *Age 35-54 as reference category. †Isolated knee osteoarthritis as
reference category
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dementia, and 49 (4.2%) died from other diseases. The
median length of follow-up among surviving patients
was 14.3 (range 13.6-15.2) years.
Table 1 shows thenumber of observed and expected
deaths and the corresponding age and sex standardised
mortality ratios for different causes of death.We found
excess all cause mortality in patients with radio-
logically confirmed osteoarthritis of the knee or hip
compared with the general population (standardised
mortality ratio 1.55, 95% confidence interval 1.41 to
1.70). We found higher rates of death in patients with
osteoarthritis compared with the general population
for all the different causes of death, but the effect was
particularly pronounced for cardiovascular (standar-
dised mortality ratio 1.71, 1.49 to 1.98) and dementia
associated mortality (1.99, 1.22 to 3.25). We found lit-
tle evidence to suggest that age standardised mortality
ratios differed between men and women.
Table 2 shows the baseline characteristics of patients
according to their survival status at the end of follow-
up. In univariable analyses, we found increased mor-
tality in men; in older patients and those with lower
socioeconomic status; in patients with previous joint
replacement; in patients with self reported
comorbidities such as cardiovascular disease, cancer,
arterial hypertension, diabetes, chronic inflammatory
disease, and eye disease; and in patients who reported
the use of paracetamol or opioids (P≤0.05). Patients
with knee or hip pain were not more likely to die than
were patients without pain (P=0.97), but patients with
walking disability were more likely to die than were
those without (hazard ratio 1.93, 95% confidence inter-
val 1.59 to 2.36; P<0.001).
Figure 2 shows results from multivariable analysis
on the association between baseline characteristics
and all cause mortality. The risk of death seemed to
be unaffected by type of osteoarthritis (P=0.58), pre-
vious joint replacement (P=0.49), obesity (P=0.11),
intake of different types of conventional analgesics or
non-steroidal anti-inflammatory drugs at baseline
(P≥0.17); self reported history of depression (P=0.83),
chronic inflammatory disease (P=0.93), or eye disease
(P=0.56); and presence of hip or knee pain at baseline
(P=0.25). Conversely, a self reported history of dia-
betes (hazard ratio 1.95, 1.31 to 2.90), cancer (2.28,
1.50 to 3.47), or cardiovascular disease (1.38, 1.12 to
1.71) and the presence of walking disability at baseline
(1.48, 1.17 to 1.86) were independently associatedwith
increased all cause mortality.
Figure 3 (top left) shows the cumulative incidence of
death fromall causes in patientswith andwithoutwalk-
ing disability at baseline: 53% of patients with walking
disability compared with 33% of patients without dis-
ability died. As indicated in table 3, the crude hazard
ratio of 1.93 (1.59 to 2.36; P<0.001) was attenuated to
1.58 (1.29 to 1.93) after adjustment for age and sex and
to 1.48 after full adjustment as reported above. In a
sensitivity analysis, the 88 patients with severe walking
disability had a higher risk of death from any cause
(fully adjusted hazard ratio 1.88, 1.37 to 2.56) than
did the 200 patients with moderate walking disability
(1.31, 1.00 to 1.70; P for trend <0.001). Figure 3 shows
that deaths from cardiovascular causes were higher in
patients with walking disability (25% v 12%; crude
hazard ratio 2.40, 1.79 to 3.23; P<0.001). Table 3 indi-
cates that the association between deaths from cardio-
vascular causes and walking disability remained after
adjustment for baseline covariates, although itwas atte-
nuated (fully adjusted hazard ratio 1.72, 1.22 to 2.41;
P=0.002). Patients with walking disability also had
higher rates of deaths from respiratory causes (4.9% v
3.4%, fully adjusted hazard ratio 1.74, 0.82 to 3.71;
P=0.15) and gastrointestinal causes (3.5% v 1.3%;
2.51, 0.89 to 7.14; P=0.08) compared with patients
without disability, but confidence intervals were wide
and P values non-significant. Rates for cancer related
death (11% v 11%; P=0.93) and death associated with
dementia (1.4% v 1.6%; P=0.58) were similar between
patients with and without walking disability at baseline
examination.
The web appendix shows results from sensitivity
analyses of all cause mortality. When we restricted
the analysis to the 885 (76%) patientswith radiographic
osteoarthritis of a Kellgren-Lawrence grade of 2 or
above, we found the associations between baseline
Table 2 | Characteristics of patients at baseline. Values are numbers (percentages) unless
stated otherwise
Characteristic at baseline
Patients died
Crude hazard ratio*
(95% CI) P value*
Yes
(n=438)
No
(n=725)
Age (years) at baseline:
<0.001
35-54 6 (1) 169 (23) 1.00 (reference)
55-74 273 (62) 503 (69) 12.4 (5.53 to 27.9)
≥75 159 (36) 53 (7) 40.7 (18.0 to 92.0)
Male sex 204 (47) 299 (41) 1.21 (1.00 to 1.46) 0.048
Lower social class (IIIM to V) 228 (52) 342 (47) 1.21 (1.00 to 1.46) 0.050
Smoking 70 (16) 115 (16) 0.94 (0.74 to 1.19) 0.60
Previous joint replacement 42 (10) 38 (5) 1.61 (1.17 to 2.22) 0.003
Type of osteoarthritis:
0.14
Knee only 130 (30) 233 (32) 1.00 (reference)
Hip only 120 (27) 222 (31) 0.98 (0.77 to 1.26)
Knee and hip 188 (43) 270 (37) 1.20 (0.96 to 1.50)
Knee or hip pain 289 (66) 477 (66) 1.00 (0.82 to 1.22) 0.97
Walking disability 152 (35) 136 (19) 1.93 (1.59 to 2.36) <0.001
Type of analgesic:
Paracetamol 209 (48) 269 (37) 1.28 (1.05 to 1.57) 0.015
Non-steroidal anti-inflammatory drugs 123 (28) 216 (30) 0.83 (0.67 to 1.03) 0.09
Opioids 142 (32) 173 (24) 1.32 (1.07 to 1.63) 0.008
Arterial hypertension 138 (32) 166 (23) 1.43 (1.17 to 1.75) 0.001
Cancer 25 (6) 16 (2) 2.11 (1.41 to 3.16) <0.001
Cardiovascular disease 152 (35) 131 (18) 1.96 (1.61 to 2.38) <0.001
Chronic inflammatory disease 163 (37) 216 (30) 1.30 (1.07 to 1.58) 0.008
Chronic obstructive pulmonary disease 77 (18) 110 (15) 1.14 (0.89 to 1.46) 0.29
Depression 40 (9) 58 (8) 1.09 (0.78 to 1.50) 0.62
Diabetes 29 (7) 18 (2) 2.10 (1.44 to 3.06) <0.001
Eye disease 67 (15) 39 (5) 2.10 (1.62 to 2.73) <0.001
Obesity 105 (24) 220 (30) 0.77 (0.62 to 0.96) 0.020
*Univariable hazard ratios, 95% confidence intervals, and P values were derived from Cox regression models
after multiple imputation of missing covariate data; hazard ratios >1 indicate lower mortality in reference
category.
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characteristics and all causemortality to be robust (web
appendix 2). Similarly, results were mostly unaffected
by a restriction of the analysis to participants with com-
plete information (web appendix 3).
DISCUSSION
In this large population based cohort study, we found
that people with symptoms and radiographical confir-
mation of osteoarthritis of the hip or knee have an
excess all cause mortality compared with the general
population. The excess was particularly pronounced
for death from cardiovascular causes and for dementia
associated mortality. Predictors of excess mortality
were diabetes, cardiovascular disease, and cancer
reported at baseline. Conversely, we did not find robust
associationswith the reporteduse of analgesics andnon-
steroidal anti-inflammatory drugs, obesity, or joint
replacement atbaseline.Themost striking finding,how-
ever, was the strong relation between excess mortality
and walking disability. Our analysis suggested that the
more severe the restriction in walking ability the more
likely a personwas to die early.Most of the excessmor-
tality associated with walking problems was due to
cardiovascular causes. We also saw a relation with
deaths from gastrointestinal disorders, but the numbers
were small and some of this may be explained by
confounders such as total use of non-steroidal anti-
inflammatory drugs or alcohol consumption.
Strengths and weaknesses
The strengths of this study include the population based
design of the cohort,2021 the large number of patients
with osteoarthritis included, and the long term follow-
up of patients for a median of 14 years.Wewere able to
ascertain the survival status of all patients included in
our study. However, we cannot rule out residual selec-
tion bias introduced by participants refusing clinical or
radiographic examination. In our analyses, we used
baseline characteristics—namely, comorbidities and
analgesic/anti-inflammatory consumption—that were
reported by patients and information given on death
certificates to derive estimates for disease specific mor-
tality. This might have resulted in misclassifications. If
misclassifications were non-differential, the observed
associations are likely to be underestimates.We cannot
exclude, however, that misclassifications were differen-
tial, which could bias estimates in either direction. The
most important limitation of this study is the missing
data for baseline covariates, which we accounted for
by using multiple imputation. This procedure is based
on the assumption that no unobserved characteristics
exist that affect missingness.27 Results are valid only if
this assumption is not violated, which is difficult to ver-
ify. As an alternative to multiple imputation, we did a
sensitivity analysis restricted to patients with complete
data for covariates and found similar results. A final lim-
itation is that wewere able to analyse drug use onlywith
data collected at baseline, which are unlikely to be
representative of the cumulative use of drugs over the
entire study period. This is likely to explain the
observed lack of evidence for an association between
use of non-steroidal anti-inflammatory drugs and mor-
tality. Finally, any radiological definition of osteoarthri-
tis may be considered arbitrary and debatable. We
chose to base our definition primarily on the presence
of grade 1 osteophytes as required for a Kellgren-Lawr-
ence grade of 1 and as used previously in this study and
others.2429 When we used an alternate definition of
osteoarthritis, however,we foundmuch the same results
(web appendix 2).
Context
Although the primary focus in research on osteoarthri-
tis has been on pain and disability, some previous stu-
dies have provided evidence thatmortality is increased
in peoplewith osteoarthritis.2 Previous studies had sev-
eral important limitations. Three studies recruited only
from hospitals or medical practices,11 12 14 one study
included only women with a specific employment
history,13 and another investigated patients after total
knee replacement.17 Of the two population based stu-
dies, one reported prevalence and the other reported
incidence but had a small sample size.12 14 16 Only three
studies reported major causes of death,11 13 17 and only
two studies described factors associated with an
increased risk of death.13 14 16 Four studies did not adjust
analyses for important prognostic factors such as
Table 3 | Associations between walking disability and mortality
Hazard ratio
(95% CI)* P value*
All cause mortality:
Crude 1.93 (1.59 to 2.36) <0.001
Age and sex adjusted 1.58 (1.29 to 1.93) <0.001
Fully adjusted 1.48 (1.17 to 1.86) 0.001
Death from cardiovascular causes:
Crude 2.40 (1.79 to 3.23) <0.001
Age and sex adjusted 1.95 (1.44 to 2.63) <0.001
Fully adjusted 1.72 (1.22 to 2.41) 0.002
Cancer related death:
Crude 1.22 (0.82 to 1.82) 0.34
Age and sex adjusted 1.06 (0.70 to 1.58) 0.80
Fully adjusted 0.98 (0.62 to 1.56) 0.93
Death from respiratory causes:
Crude 1.74 (0.90 to 3.34) 0.10
Age and sex adjusted 1.37 (0.70 to 2.66) 0.36
Fully adjusted 1.74 (0.82 to 3.71) 0.15
Death fromgastrointestinal causes:
Crude 3.26 (1.32 to 8.06) 0.010
Age and sex adjusted 2.46 (0.98 to 6.20) 0.06
Fully adjusted 2.51 (0.89 to 7.14) 0.08
Death associated with dementia:
Crude 1.15 (0.37 to 3.63) 0.81
Age and sex adjusted 0.68 (0.21 to 2.19) 0.52
Fully adjusted† 0.69 (0.18 to 2.59) 0.58
*Hazard ratios, 95% confidence intervals, and P values were derived
from Cox proportional hazards models after multiple imputation of
missing covariate data; hazard ratios >1 indicate higher mortality in
patients with walking disability at baseline.
†Not adjusted for history of obesity, diabetes, depression, and cancer
owing to collinearity.
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smoking history or obesity.11 12 15 18 Ours is the first
study to investigate patterns and causes of incident
mortality in a large population based sample of people
with osteoarthritis, overcoming many of the limita-
tions of previous studies.
Explanations
Most deathswere due to cardiovascular causes, and the
associationbetweendeaths fromall causes andwalking
disability is driven largely by deaths due to cardio-
vascular causes. We found no evidence that cancer
related deaths and deaths associated with dementia
are related to increased walking disability, which sug-
gests that other pathways are more relevant in these
cases. Two main possible explanations exist for our
findings. Firstly, reduced physical activity may lead
to reduced protection against cardiovascular disease.
Alternatively, patients with osteoarthritis may have
chronic smouldering inflammation with increased
levels of inflammatory cytokines, such as increased cir-
culating concentrations of interleukin 6 and tumour
necrosis factor α, possibly as a result of ongoing tissue
damage.30 31 This chronic inflammation may be cau-
sally involved in various chronic conditions, such as
cardiovascular and neurodegenerative disease, dia-
betes, or cancer.32 We found increased rates of cardio-
vascular, cancer, and dementia associated deaths,
which would be fully concordant with this reasoning.
Wagner et al recently reported an increased risk of can-
cer in patients with arthroplasty compared with the
general population.33 Although the authors suggested
that this increase in risk may be caused by the prosthe-
sis material, we hypothesise that arthroplasty was a
mere surrogate marker for osteoarthritis, which in
turn was associated with chronic inflammation and
subsequent increase in the risk of cancer. A third pos-
sibility is that the use of non-steroidal anti-inflamma-
tory drugs is a major factor in the excess mortality of
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people with osteoarthritis. Although our findings do
not directly support this, a recently published network
meta-analysis by our group indicates that this may be
the case.34 Six out of seven non-steroidal anti-inflam-
matory drugs were associated with clinically relevant
twofold to fourfold increases in the risk of myocardial
infarction, stroke, or cardiovascular death compared
with placebo.34
We found a protective effect of obesity on overall
mortality in univariable analysis and—albeit statisti-
cally non-significant—in multivariable analysis. This
phenomenon is known as the obesity paradox:
whereas obesity itself is associated with an increased
risk of developing conditions such as coronary artery
disease or hypertension, once the condition is mani-
fest, obesity seems to be protective.35 Explanations
include lower vascular resistance and plasma renin
activity in obese patients with an established condition
that is in turn associated with cardiovascular events,
compared with lean patients with the same
condition.35 Alternatively, obese and non-obese
patients may have different disease phenotypes result-
ing in better prognosis in obese patients: cardio-
vascular conditions that are mainly caused by obesity
and associated risk factorsmayhave amore favourable
prognosis than cardiovascular conditions in non-obese
patients with a strong genetic predisposition for the
condition.35 The paradox was established for a range
of conditions and phenotypes, including old age and
rheumatoid arthritis. To our knowledge, however, we
are the first to establish the obesity paradox formortal-
ity in patients with osteoarthritis.
Implications
Webelieve that these data have important implications
for the ways in which people presenting with osteoar-
thritis should bemanaged. If a patient has symptoms of
osteoarthritis with associated walking disability, then
he or she is at a clearly increased risk of premature
death from cardiovascular disease. This means that
healthcare professionals seeing such people should
assess and consider treating all cardiovascular risk
factors, including hypertension, hyperlipidaemia,
smoking, and physical inactivity. We suggest that doc-
tors should approach themanagement of their patients
with osteoarthritis much as they would for those who
present with gout—that is, by using the presenting con-
dition as a red flag for premature cardiovascular
death.36-38 Wagenmakers et al put forward such an
approach in the context of joint replacement.39 These
authors suggested that the aim of an intervention for
osteoarthritis such as joint replacement should be to
get people back to a level of activity that would fit
with the World Health Organization’s recommenda-
tions for minimum exercise required to help prevent
cardiovascular disease and developed a measurement
instrument to assess such an outcome.39 Increased phy-
sical activity has been suggested to reduce the overall
mortality and risk of ischaemic heart disease in
men,40 41 and it is known to be of value to people with
osteoarthritis in many other ways, reducing pain and
depression, for example.42-45 An aggressive approach
to helping people to become more active, in the face
of painful osteoarthritis, thus seems fully justified.
Conclusions
In this large population based study, we found an
excess mortality in people with symptoms and radio-
graphic confirmation of osteoarthritis of the knee or
hip comparedwith the general population, irrespective
of the cause of death. The most important risk factors
for all cause mortality in osteoarthritis (besides older
age and male sex) were a history of diabetes, cardio-
vascular disease, or cancer and increased walking dis-
ability. In patients with walking disability, the risk of
death from cardiovascular causes was increased. We
conclude that the management of patients with
osteoarthritis and walking disability should focus on
effective treatment of cardiovascular risk factors and
comorbidities and on helping people to increase their
level of physical activity.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Osteoarthritis is the most common rheumatic disease in elderly people
Morbidity associated with osteoarthritis has been extensively studied, but associated
mortality is less well documented
Several studies have suggested an increased risk of death in people with osteoarthritis, but
many of these studies had methodological problems
WHAT THIS STUDY ADDS
Patients with osteoarthritis have an excess mortality compared with the general population
Major risk factors associated with increased mortality in osteoarthritis patients are walking
disability and a history of cancer, diabetes, and cardiovascular disease
Patients with osteoarthritis and walking disability are at increased risk of death from
cardiovascular causes, so management of such patients should focus on effective treatment
of cardiovascular risk factors
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